Tirzepatide Smoking Cessation Study
The purpose of this study is to evaluate the effects of the investigational use of a GLP-1 medication called tirzepatide (Zepbound) on cigarette smoking, cigarette craving, and related outcomes.
Why this Research Matters
During the research study, you will have a physical exam and lab tests, give urine and blood samples, do breathalyzer tests, answer questions and complete questionnaires, use an app on your phone, use a nicotine patch, and take an injectable study medication or a placebo.
Who can Participate
Inclusion criteria: - Age 21-65 - Daily cigarette smoker - Interested in reducing or stopping your cigarette use - Overweight (body mass index of 25 or higher) Not everyone will qualify to be in the study. Other inclusion and exclusion criteria will be evaluated by the study team.
Study ID
Protocol Number: 26-0258
More information available at ClinicalTrials.gov: NCT07602699
Meet the Team
Principal Investigator